



DIASORIN SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT FOR THE LIAISON NES[®] MOLECULAR POINT-OF-CARE PLATFORM AND THE FLU A/B, RSV & COVID-19 PANEL

- DIASORIN SIGNS AN EXCLUSIVE U.S. HOSPITAL-CHANNEL DISTRIBUTION AGREEMENT WITH FISHER SCIENTIFIC, PART OF THERMO FISHER SCIENTIFIC, FOLLOWING FDA 510(k) CLEARANCE AND CLIA-WAIVER OF THE LIAISON NES[®] PLATFORM'S FIRST ASSAY;
- THE LIAISON NES[®] ENABLES RAPID, LAB-QUALITY MOLECULAR DIAGNOSTICS TO NEAR-PATIENT SETTINGS, DELIVERING RESULTS IN ~15 MINUTES WITH A SIMPLE THREE-STEP WORKFLOW;
- THE AGREEMENT EXPANDS DIASORIN'S COMMERCIAL PENETRATION IN THE U.S. HOSPITAL MARKET, WHILE THE COMPANY PROGRESSES ADDITIONAL DISTRIBUTION AGREEMENTS TO ACCESS THE NON-ACUTE PHYSICIAN OFFICE LAB (POL) SEGMENT.

Saluggia, Italy - January 26, 2026 - Diasorin (FTSE MIB: DIA) announced today that, following the recent 510(k) clearance and CLIA-waiver from the U.S. Food and Drug Administration (FDA) for its first assay—the FLU A/B, RSV & COVID-19 Panel for use on the LIAISON NES[®] platform—the Company has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific, for the LIAISON NES[®] molecular point-of-care (POC) platform in the U.S. hospital market.

The LIAISON NES[®] is a next-generation molecular POC system designed to expand access to high-quality diagnostic testing in decentralized settings. Its fully automated workflow requires only a few seconds of hands-on time and delivers results in approximately 15 minutes, enabling timely clinical decisions while reducing dependence on specialized laboratory personnel.

The U.S. represents one of the largest global markets for molecular respiratory testing, with over 7,000 hospitals and approximately 130,000 POLs performing such diagnostics. Fisher Scientific's strong footprint and established relationships across the hospital channel make it a strategic partner for the introduction and scale-up of the LIAISON NES[®] platform and its respiratory panel.

The agreement strengthens Diasorin's commercial capabilities in the hospital segment, complementing the Company's existing U.S. commercial organization, which today promotes Diasorin's molecular solutions—including LIAISON[®] MDX and LIAISON[®] PLEX—as well as the recently expanded salesforce dedicated to the LIAISON NES[®] program.

"This agreement will accelerate our entry into the hospital segment and support access to major U.S. Integrated Delivery Networks (IDNs)," commented Carlo Rosa, CEO of Diasorin. "We are also working to finalize additional distribution agreements with others in the United States aimed at providing full coverage of the non-acute market segment, which includes more than 130,000 POLs, ensuring a comprehensive and efficient go-to-market strategy across all key customer categories".



About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo

Corporate Investor Relations & ESG Senior Analyst
eugenia.ragazzo@diasorin.com